Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 428 | 59 | 364 |
| Samples | 274 | 41 | 230 |
| Peptides | 197 | 32 | 172 |
Function
NCF4 · Neutrophil cytosolic factor 4
The protein encoded by this gene is a cytosolic regulatory component of the superoxide-producing phagocyte NADPH-oxidase, a multicomponent enzyme system important for host defense. This protein is preferentially expressed in cells of myeloid lineage. It interacts primarily with neutrophil cytosolic factor 2 (NCF2/p67-phox) to form a complex with neutrophil cytosolic factor 1 (NCF1/p47-phox), which further interacts with the small G protein RAC1 and translocates to the membrane upon cell stimulation. This complex then activates flavocytochrome b, the membrane-integrated catalytic core of the enzyme system. The PX domain of this protein can bind phospholipid products of the PI(3) kinase, which suggests its role in PI(3) kinase-mediated signaling events. The phosphorylation of this protein was found to negatively regulate the enzyme activity. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 143 amino-acid changes on canonical ENST00000248899 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NCF4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NCF4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Endometrial Carcinoma | 1/42 2% | 15/612 2% |
| Melanoma | 3/210 1% | 35/1899 2% |
| Colorectal Carcinoma | 8/143 6% | 34/3239 1% |
| Other Solid Cancers | 2/94 2% | 16/1515 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 13/1390 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Biliary Tract Carcinoma | 1/54 2% | 6/950 1% |
| Gastric Carcinoma | 0/74 0% | 12/1809 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 10/2550 0% |
| Hepatocellular Carcinoma | 2/46 4% | 10/2210 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Pancreatic Carcinoma | 0/89 0% | 8/1611 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Ovarian Carcinoma | 1/109 1% | 4/998 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Carcinoma | 2/23 9% | 1/769 0% |
| Glioma | 1/52 2% | 7/2127 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Prostate Carcinoma | 0/13 0% | 7/2105 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 1/2534 0% |
Mutation Distribution
Where NCF4 is mutated · all tissues, split by cell line vs tissue
How many mutations in NCF4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 428 mutations in NCF4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|